Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and anticancer drugs in Peru.

According to the company, its biosimilar for autoimmune disease treatment Remsima (infliximab) was awarded in a bid by Seguro Social de Salud (EsSalud) in Peru. It will be supplied for one year starting this month. 

The company explained that this bid accounted for 81% of the total volume of infliximab-based treatments in Peru.

Celltrion's anticancer biosimilar Herzuma (trastuzumab) for breast and gastric cancers won a supply contract through a bid by the Peruvian Ministry of Health and will be supplied for one year starting from July.

The company will supply four products to Peru, including the blood cancer treatment Truxima (rituximab) and the autoimmune disease treatment Yuflyma (adalimumab), awarded in bids by Peruvian public institutions in February.

The anticancer drug Vegzelma (bevacizumab) is scheduled to be launched in Peru this month.

Write to Jeong Min Nam at peux@hankyung.com